European ATTR (EU-ATTR) - 5th International ATTR Amyloidosis Meeting for Patients and Doctors

September 25 - 26, 2025

Wainua (eplontersen)
ATTR amyloidosis

PDF

Eplontersen slows disability progression and deterioration of gait speed in patients with hereditary transthyretin amyloidosis with polyneuropathy

PDF

Estimating meaningful differences in measures of autonomic symptom impairment and overall disability in patients with hereditary transthyretin amyloidosis with polyneuropathy

PDF

Long-term efficacy and safety of eplontersen in patients with hereditary transthyretin amyloidosis with polyneuropathy: initial report from the open-label extension of the NEURO-TTRansform study

PDF

Early Symptoms and Medical History of Patients with Transthyretin Amyloidosis Cardiomyopathy: Results from the Multi-Country OverTTuRe Study

PDF

MaesTTRo: Initial experience from a prospective, non-interventional, multi-country study of patients with amyloid transthyretin amyloidosis

Real-world post-diagnosis treatment patterns and outcomes in patients with ATTR amyloidosis: Results from the multi-country OverTTuRe study

Characteristics, treatment patterns and outcomes of patients with hereditary transthyretin amyloidosis: an observational, retrospective study in China (OverTTuRe)

Quality standards for the diagnosis and management of ATTR and AL amyloidosis: A nominal group technique study

Understanding Care Pathways in Cardiac Amyloidosis: Gaps and Opportunities for Early Diagnosis and Treatment

Incidence, patient characteristics and clinical outcomes of amyloid polyneuropathy: an observational study in England using electronic health records

Evolving trends in ATTR amyloidosis: an analysis of the retrospective cohort CARDINAL study in Portugal

PDF

A real-world study of health-related quality of life among patients with transthyretin amyloidosis with polyneuropathy

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Request a field medical follow-up

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person

What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.

I am not a healthcare professional practicing in the United States (Take me to AstraZeneca.com)